Overview

Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2030-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab combined with Bevacizumab for the first-line treatment of advanced HCC

Phase:

PHASE3

Details

Lead Sponsor:

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Treatments:

Bevacizumab
sintilimab